Tag Archives: The Stem Cell Blog

Upfront Use of Immunotherapy for NCSLC – OncLive

OncLiveUpfront Use of Immunotherapy for NCSLCOncLivePanelists: Mark A. Socinski, MD, Florida Hospital Cancer Institute; Tracey L. Evans, MD, University of Pennsylvania; Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center; Vali A. Papadimitrako… Continue reading

Less Common Side Effects With Immunotherapy in Melanoma – OncLive

OncLiveLess Common Side Effects With Immunotherapy in MelanomaOncLiveInsights From: Michael A. Postow, MD, Memorial Sloan Kettering Cancer Center; Claire Crowley, RN, Memorial Sloan Kettering Cancer Center; Michael B. Atkins, MD, Georgetown Lombardi Co… Continue reading

Agricultural Biotechnology: Emerging Technologies and Global Markets – Yahoo Finance

Agricultural Biotechnology: Emerging Technologies and Global MarketsYahoo FinanceBiotechnology tools include DNA sequencing, biochips, RNA interference, synthetic biology, and genome editing. Genomics enabled products include biotech seeds and syntheti… Continue reading

Chardan Capital Markets Starts CRISPR Therapeutics (CRSP) at Buy – StreetInsider.com

Chardan Capital Markets Starts CRISPR Therapeutics (CRSP) at Buy StreetInsider.com Chardan Capital Markets initiates coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Buy rating and a price target of $23.50. Analyst Madhu Kumar commented, “We initiate coverage of CRISPR Therapeutics (CRSP, or CRISPR Tx) with a Buy rating … Crispr Therapeutics AG – Receive News & Ratings DailyBBNS Analysts Set $27.00 Target Price for Crispr Therapeutics AG (CRSP)Sports Perspectives Stock Analysts Favoring These Names: CRISPR Therapeutics AG (:CRSP) USD Partners LP (NYSE:USDP)Sherwood Daily The Cerbat Gem all 6 news articles »

Chardan Capital Markets Starts CRISPR Therapeutics (CRSP) at Buy StreetInsider.com Analyst Madhu Kumar commented, “We initiate coverage of CRISPR Therapeutics (CRSP, or CRISPR Tx) with a Buy rating (PT $23.50), on our view of possible upside on clinical leadership in CRISPR therapy overriding the risk of possible downside on the …

ImMAGE Biotherapeutics’ DNA immunotherapy shows high efficacy with low toxicology results PR Newswire (press release) BETHESDA, Md., March 27, 2017 /PRNewswire-USNewswire/ — ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company, announced today that its immunotherapy successfully passed early toxicology and efficacy studies.